Compare up to 40 stocks
Compared Stocks: 1 / 40
| Name | Sector | Price | Volume | Market Cap | P/E Ratio | Dividend Yield | Analyst Consensus | Analyst Price Target | Smart Score | Leveraged ETF | Article | Follow |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
 EOLS | Healthcare | $6.96 | 455.37K | $460.67M | -14.87 | ― | Strong Buy |
| Ticker | Company Name | Price | Change | % Change | |
|---|---|---|---|---|---|
| EOLS | Evolus | 6.96 | -0.26 | -3.60% |
| Name | Price | % Change | |
|---|---|---|---|
| EOLS | $6.96 | -3.60% |
Evolus, Inc. (($EOLS)) has held its Q3 earnings call. Read on for the main highlights of the call. Evolus delivered a strongly positive earnings call, highlighted by 13% third-quarter revenue
BTIG analyst Sam Eiber raised the firm’s price target on Evolus (EOLS) to $15 from $13 and keeps a Buy rating on the shares. The firm cites the company’s modest
Reports Q3 revenue $78M, consensus $77.58M. “Our third quarter results demonstrate the continued strength of our commercial execution and the progress we are making in building a diversified global performance
Backs FY26 adjusted gross profit margin view 67%-67.5%. Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>> See today’s best-performing stocks on TipRanks
Evolus (EOLS) announced that it has entered into an option agreement with a privately held company developing a novel, procedure-based, sustained-release injectable treatment for hair restoration. The agreement advances Evolus’
The FDA posted a letter sent to Evolus (EOLS) regarding the company’s promotional communication for Jeuveau. The FDA determined an Instagram post is “false or misleading.” It told the company,
10:19 EDT Evolus (EOLS) falls 5% to $7.12 after FDA send letter over marketing Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Evolus (EOLS) announced the launch of Wings by Evolus, a new charitable platform designed to bring together aesthetic practices, providers, and patients to support organizations and causes that positively impact
Mizuho notes that Evolus (EOLS) shares were down 8% today and believes the relative underperformance is likely macro-driven and potentially reflective of profit-taking following the stock’s recent outperformance. However, the
Telix Pharmaceuticals (TLX) announced that David Gill has been appointed Chair of the Board, effective immediately. Gill joined Telix as a Non-Executive Director in May 2026 as part of the
| Name | Upcoming Earnings Date | Market Cap | EPS Forecast | Sales Forecast | PEG Ratio | P/E Ratio |
|---|---|---|---|---|---|---|
| EOLS | Mar 9, 2027TBA | $460.67M | $0.06 | $99.12M | 6.73 | -14.87 |
Compare Stocks Side-by-Side
Our stock comparison tool allows investors to compare multiple stocks simultaneously, providing comprehensive insights into key metrics, financial data, and analyst ratings. Make informed investment decisions by analyzing stocks side by side.
Key Features of Our Stock Comparison
How to Use the Stock Comparison Tool
Simply enter the ticker symbols of the stocks you want to compare in the search box above. You can add up to 40 stocks at once. The tool will automatically populate comparison tables with the latest data, allowing you to analyze and contrast different investment opportunities across various sectors and industries.
Popular Stock Comparisons
Investors frequently compare stocks within the same sector to identify the best investment opportunities. Popular comparisons include tech giants like Apple (AAPL) vs. Microsoft (MSFT), semiconductor leaders Nvidia (NVDA) vs. AMD, beverage companies Coca-Cola (KO) vs. Pepsi (PEP), and electric vehicle makers Tesla (TSLA) vs. Rivian (RIVN).
Why Compare Stocks?
Comparing stocks helps investors identify which companies offer the best value, growth potential, and risk-adjusted returns. By analyzing multiple stocks side by side, you can better understand relative valuations, competitive advantages, and market positioning before making investment decisions.
